Biomarkers in hemodialysis patients

Area of Science:

• Nephrology and Cardiology
• Biomarker Discovery and Application

Background:

• Patients with chronic kidney disease (CKD) exhibit a significantly elevated risk for cardiovascular disease (CVD) compared to the general population.
• Cardiovascular disease in CKD encompasses conditions such as sudden death, coronary artery disease (CAD), heart failure (HF), stroke, and peripheral artery disease.
• Renal insufficiency is a potent, independent predictor of mortality across all stages of CKD, highlighting the critical link between kidney function and patient outcomes.

Purpose of the Study:

• To review the diagnostic and prognostic utility of novel cardiovascular biomarkers in patients with chronic kidney disease (CKD) and end-stage renal failure.
• To explore how biomarkers can aid in the early diagnosis and therapeutic guidance for CVD in the context of compromised kidney function.
• To address the complex interplay of traditional and non-traditional risk factors contributing to CVD in CKD patients and the limitations of current risk assessment tools.

Main Methods:

• Literature review focusing on recent advancements in cardiovascular biomarker research relevant to kidney disease.
• Analysis of studies investigating the predictive value of biomarkers such as brain natriuretic peptide (BNP), cardiac troponins (cTns), inflammatory markers, adhesion molecules, and asymmetric dimethylarginine (ADMA).
• Examination of the role of these biomarkers in assessing cardiovascular risk and outcomes specifically within CKD populations.

Main Results:

• Several novel biomarkers, including BNP, cardiac troponins, inflammatory markers, adhesion molecules, and ADMA, have emerged as significant predictors of cardiovascular outcomes in CKD.
• These biomarkers show potential for improving the accuracy of cardiovascular risk stratification beyond traditional risk factors in patients with impaired kidney function.
• The complex risk factor profiles in CKD patients, including seemingly paradoxical associations, necessitate advanced tools like biomarkers for precise etiological assessment.

Conclusions:

• Novel cardiovascular biomarkers hold significant promise for enhancing the early diagnosis, prognosis, and management of CVD in patients with CKD and end-stage renal failure.
• These biomarkers can provide crucial insights into cardiovascular risk and outcomes, aiding clinicians in making more informed therapeutic decisions.
• Further research is warranted to fully integrate these biomarkers into routine clinical practice for optimizing cardiovascular care in nephrology patients.